121 related articles for article (PubMed ID: 7744141)
21. Secondary treatment of advanced cancer of the prostate with Zoladex.
Klarskov P; Lund F; Petersen SE
Int Urol Nephrol; 1990; 22(4):359-62. PubMed ID: 2146234
[TBL] [Abstract][Full Text] [Related]
22. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O; Kontturi M
Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
[TBL] [Abstract][Full Text] [Related]
23. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
[TBL] [Abstract][Full Text] [Related]
24. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
[TBL] [Abstract][Full Text] [Related]
25. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial.
Zinner NR; Bidair M; Centeno A; Tomera K
Urology; 2004 Dec; 64(6):1177-81. PubMed ID: 15596193
[TBL] [Abstract][Full Text] [Related]
26. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
[TBL] [Abstract][Full Text] [Related]
27. Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research Group.
Emtage LA; Trethowan C; Hilton C; Kelly K; Blackledge GR
Am J Clin Oncol; 1988; 11 Suppl 2():S173-5. PubMed ID: 2977273
[TBL] [Abstract][Full Text] [Related]
28. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
[TBL] [Abstract][Full Text] [Related]
29. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
[TBL] [Abstract][Full Text] [Related]
30. U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.
Ryan PG; Peeling WB
Am J Clin Oncol; 1988; 11 Suppl 2():S169-72. PubMed ID: 2977272
[TBL] [Abstract][Full Text] [Related]
31. LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy--a phase II study.
Iversen P; Rose C; Stage JG; Iversen HG; Hansen RI; Hvidt V; Mogensen P; Pedersen T; Hansen JB
Scand J Urol Nephrol; 1989; 23(3):177-83. PubMed ID: 2529629
[TBL] [Abstract][Full Text] [Related]
32. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
Di Silverio F; Serio M; D'Eramo G; Sciarra F
Eur Urol; 1990; 18 Suppl 3():54-61. PubMed ID: 2151278
[TBL] [Abstract][Full Text] [Related]
33. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group.
Soloway MS; Chodak G; Vogelzang NJ; Block NL; Schellhammer PF; Smith JA; Scott M; Kennealey G; Gau TC
Urology; 1991 Jan; 37(1):46-51. PubMed ID: 1824732
[TBL] [Abstract][Full Text] [Related]
34. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer.
Sharifi R; Bruskewitz RC; Gittleman MC; Graham SD; Hudson PB; Stein B
Clin Ther; 1996; 18(4):647-57. PubMed ID: 8879893
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer.
Perren TJ; Clayton RN; Blackledge G; Bailey LC; Holder G; Lynch SS; Arkell DG; Cottam J; Farrar D; Young CH
Cancer Chemother Pharmacol; 1986; 18(1):39-43. PubMed ID: 2944668
[TBL] [Abstract][Full Text] [Related]
36. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
Peeling WB
Urology; 1989 May; 33(5 Suppl):45-52. PubMed ID: 2523611
[TBL] [Abstract][Full Text] [Related]
37. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate.
Khan MS; O'Brien A
Urol Int; 1998; 60(1):33-40. PubMed ID: 9519419
[TBL] [Abstract][Full Text] [Related]
38. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.
Kaisary AV; Tyrrell CJ; Peeling WB; Griffiths K
Br J Urol; 1991 May; 67(5):502-8. PubMed ID: 1828183
[TBL] [Abstract][Full Text] [Related]
39. Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial.
Metz R; Namer M; Adenis L; Audhuy B; Bugat R; Colombel P; Couette JE; Grise P; Khater R; LePorz B
Am J Clin Oncol; 1988; 11 Suppl 2():S112-4. PubMed ID: 2977263
[TBL] [Abstract][Full Text] [Related]
40. [Quality of life following endocrine therapy for advanced prostate cancer: a comparative study between LH-RH agonist 1-month depot and 3-month depot].
Namiki S; Ishidoya S; Saito S; Mitsukawa S; Suzuki Y; Numata I; Arai Y
Nihon Hinyokika Gakkai Zasshi; 2008 Jul; 99(5):631-7. PubMed ID: 18697469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
